Source: International Congress 2018 – New developments in the treatment of asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. Hanania (Houston, United States of America), J. Fang (East Hanover, United States of America), Z. Wei (Morristown, United States of America), B. Ortiz (East Hanover, United States of America), A. Kavati (East Hanover, United States of America), X. Jaumont (Basel, Switzerland), L. Alvares (Basel, Switzerland), H. Cao (East Hanover, United States of America). Real-world effectiveness of omalizumab in allergic asthma patients with low or high blood eosinophils: A retrospective claims analysis study. 1029

Member's Comments

No comment yet.

Related content which might interest you: Effectiveness of omalizumab in Canadian patients with allergic asthma: A retrospective study. Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Impact of subcutaneous allergoid AIT on patients with allergic rhinitis and/or asthma: A retrospective real-life, long-term cohort analysis Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020 Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis Source: Eur Respir J, 56 (4) 2000151; 10.1183/13993003.00151-2020 Year: 2020 Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 Dispensed asthma therapy and medical resource utilisation in asthma patients: results from the L777 observational study Source: Annual Congress 2009 - Epidemiology of asthma Year: 2009 The APEX study: A retrospective review of responses of severe allergic asthma patients to omalizumab on continuous or non-continuous oral corticosteroids in UK clinical practice Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011 Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012 Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Pooled data from 3 UK centres Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011 Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Pooled data from 4 UK centres Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 What predicts poor collection of medication among children with asthma? A case-control study Source: Eur Respir J 2002; 20: 1464-1469 Year: 2002 Characteristics of children with asthma and blood eosinophilia: an observational study Source: Virtual Congress 2021 – Biomarkers and risk factors in childhood asthma Year: 2021 Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study Source: Eur Respir J, 51 (5) 1702523; 10.1183/13993003.02523-2017 Year: 2018 Real-life effectiveness of omalizumab in difficult-to-treat versus severe asthma: a national cohort study in Belgium Source: ERJ Open Res, 5 (4) 00253-2018; 10.1183/23120541.00253-2018 Year: 2019 Long-term effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: Real-life data from 3 UK centres Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 The APEX study: Retrospective review of oral corticosteroid use in omalizumab-treated severe allergic asthma patients in UK clinical practice Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011 Utility of adherence checks in patients with severe asthma eligible for biologics: a single centre retrospective analysis Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma at a single UK hospital Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Biomarker measurement in asthma patients receiving biologic therapy: a real-world retrospective study Source: International Congress 2018 – Eosinophils in airway disease Year: 2018 A single-center observational study assessing response to mepolizumab in severe eosinophilic asthma Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019